Infectex Announces Preliminary Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis

The results were presented by principal investigator Prof. S.E.Borisov in his report “Effectiveness and safety of new anti-tuberculosis product SQ109” in Scientific and Practical Conference “Innovation Technologies in Phthisiology” (Moscow,  November 24, 2016). Results presented in the report demonstrate satisfactory profile of safety and tolerability of SQ109 as well as the increase in effectiveness of the standard regimen of chemotherapy in combination with SQ109 in patients with multidrug-resistant tuberculosis.